Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study.

Aspergillosis Aspergillus spp. CAPA COVID-19 SARS-CoV-2 amphotericin-B prophylaxis solid-organ transplant recipients

Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2023
Historique:
received: 13 02 2023
accepted: 07 04 2023
medline: 16 5 2023
pubmed: 14 5 2023
entrez: 14 5 2023
Statut: epublish

Résumé

COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a frequent complication in the intensive care unit (ICU). However, little is known about this life-threatening fungal superinfection in solid organ transplant recipients (SOTRs), including whether targeted anti-mold prophylaxis might be justified in this immunosuppressed population. We performed a multicentric observational retrospective study of all consecutive ICU-admitted COVID-19 SOTRs between August 1, 2020 and December 31, 2021. SOTRs receiving antifungal prophylaxis with nebulized amphotericin-B were compared with those without prophylaxis. CAPA was defined according the ECMM/ISHAM criteria. Sixty-four SOTRs were admitted to ICU for COVID-19 during the study period. One patient received antifungal prophylaxis with isavuconazole and was excluded from the analysis. Of the remaining 63 SOTRs, nineteen (30.2%) received anti-mold prophylaxis with nebulized amphotericin-B. Ten SOTRs who did not receive prophylaxis developed pulmonary mold infections (nine CAPA and one mucormycosis) compared with one who received nebulized amphotericin-B (22.7% vs 5.3%; risk ratio 0.23; 95%CI 0.032-1.68), but with no differences in survival. No severe adverse events related to nebulized amphotericin-B were recorded. SOTRs admitted to ICU with COVID-19 are at high risk for CAPA. However, nebulized amphotericin-B is safe and might reduce the incidence of CAPA in this high-risk population. A randomized clinical trial to confirm these findings is warranted.

Identifiants

pubmed: 37180450
doi: 10.3389/fcimb.2023.1165236
pmc: PMC10174318
doi:

Substances chimiques

Amphotericin B 7XU7A7DROE
Antifungal Agents 0

Types de publication

Observational Study Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1165236

Informations de copyright

Copyright © 2023 Rombauts, Bodro, Daniel Gumucio, Carbonell, Favà, Lladó, González-Costello, Oppenheimer, Castel-Lavilla, Len, Marquez-Algaba, Nuvials-Casals, Martínez González, Lacasa, Carratalà and Sabé.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet Respir Med. 2022 Feb;10(2):180-190
pubmed: 34843666
Crit Care. 2021 Aug 19;25(1):298
pubmed: 34412686
Med Mycol. 2021 Jan 4;59(1):110-114
pubmed: 32914189
Transpl Int. 2016 Jan;29(1):51-62
pubmed: 26339864
Am J Transplant. 2022 May;22(5):1496-1497
pubmed: 34971486
Antimicrob Agents Chemother. 2014 May;58(5):2775-80
pubmed: 24590477
Curr Opin Pharmacol. 2015 Oct;24:38-44
pubmed: 26218924
J Microbiol Immunol Infect. 2022 Apr;55(2):291-299
pubmed: 33840605
Int J Pharm. 2012 Oct 15;436(1-2):106-10
pubmed: 22814222
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Crit Care. 2021 Sep 15;25(1):335
pubmed: 34526087
Am J Transplant. 2021 Jul;21(7):2509-2521
pubmed: 33278850
Am J Transplant. 2012 Jul;12(7):1929-35
pubmed: 22486950
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
Clin Microbiol Infect. 2022 Apr;28(4):580-587
pubmed: 34454093
Transplant Proc. 2010 Oct;42(8):3014-6
pubmed: 20970596
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38
pubmed: 29544767
Clin Infect Dis. 2008 May 1;46(9):1401-8
pubmed: 18419443
Antimicrob Agents Chemother. 2014 Oct;58(10):5650-7
pubmed: 24957831
Clin Microbiol Infect. 2022 Aug;28(8):1057-1065
pubmed: 35289294
Front Med (Lausanne). 2021 Nov 16;8:753659
pubmed: 34869450
Am J Transplant. 2009 Dec;9 Suppl 4:S180-91
pubmed: 20070679
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0028322
pubmed: 35506698
Clin Infect Dis. 2018 Oct 30;67(10):1621-1630
pubmed: 29860307

Auteurs

Alexander Rombauts (A)

Department of Infectious Diseases, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Marta Bodro (M)

Department of Infectious Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.

Victor Daniel Gumucio (V)

Department of Intensive Care Medicine, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Irene Carbonell (I)

Department of Infectious Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.

Àlex Favà (À)

Renal Transplant Unit, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Laura Lladó (L)

Liver Transplant Unit, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

José González-Costello (J)

Heart Transplant Unit, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Federico Oppenheimer (F)

Renal Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain.

María Ángeles Castel-Lavilla (MÁ)

Heart Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain.

Oscar Len (O)

Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Ester Marquez-Algaba (E)

Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

Xavier Nuvials-Casals (X)

Department of Intensive Care Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Daniel Martínez González (D)

Department of Intensive Care Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Judith Sacanell Lacasa (JS)

Department of Intensive Care Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Jordi Carratalà (J)

Department of Infectious Diseases, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L´Hospitalet de Llobregat, Barcelona, Spain.

Nuría Sabé (N)

Department of Infectious Diseases, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH